Rituximab combined with doxorubicin down-regulated PRDM1β expression. B-lymphoma cell lines and primary DLBCL cells expressed PRDM1α and PRDM1β both at transcriptional (A) and protein levels (B). Combined treatment of doxorubicin and rituximab reduced PRDM1β expression (C-D).